Trials / Recruiting
RecruitingNCT07157774
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 10,450 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Muvalaplin | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2025-09-02
- Primary completion
- 2031-03-01
- Completion
- 2031-03-01
- First posted
- 2025-09-05
- Last updated
- 2026-03-24
Locations
750 sites across 27 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Greece, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Slovakia, South Korea, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07157774. Inclusion in this directory is not an endorsement.